Endo, Impax Nailed With New Generic Opana Antitrust Suit
Endo Pharmaceuticals Inc. and Impax Laboratories Inc. were hit with a proposed antitrust class action in Illinois federal court Thursday, alleging Endo paid the generics manufacturer over $112 million in exchange...To view the full article, register now.
Already a subscriber? Click here to view full article